论文部分内容阅读
目的:探讨20%吡拉西坦注射液治疗颅内肿瘤术后高颅内压临床疗效和安全性。方法:选择2009年4月～2012年4月在我院神经外科住院治疗的136例颅内肿瘤术后高颅内压患者为研究对象,随机将其分为对照和实验组,对照组患者给予20%甘露醇快速静脉滴注治疗,而实验组患者则给予20%吡拉西坦快速静脉滴注治疗,比较两组患者临床疗效和不良反应发生情况。结果:实验组患者的治疗总有效率(95.59%)明显高于对照组的(85.29%),差异有显著性(P<0.05),且对照组和实验组患者在不良反应发生率方面差异无显著性(P>0.05)。结论:20%吡拉西坦注射液治疗颅内肿瘤术后高颅内压临床疗效确切,降颅压疗效好,安全可靠,不良反应少。
Objective: To investigate the clinical efficacy and safety of 20% piracetam injection in patients with intracranial tumors after intracranial hypertension. Methods: Thirty-six patients with intracranial intracranial pressure after intracranial tumor treatment in our hospital from April 2009 to April 2012 were enrolled in this study. Patients were randomly divided into control group and experimental group. Patients in control group 20% mannitol by rapid intravenous infusion, while the experimental group was given 20% piracetam rapid intravenous infusion, the clinical efficacy and adverse reactions in both groups were compared. Results: The total effective rate (95.59%) in the experimental group was significantly higher than that in the control group (85.29%) (P <0.05), and there was no significant difference in the incidence of adverse reactions between the control group and the experimental group Significance (P> 0.05). Conclusion: The clinical effect of intracranial intracranial pressure after 20% piracetam injection in treatment of intracranial high intracranial pressure is exact, and the effect of reducing intracranial pressure is good, safe and reliable with few adverse reactions.